Expert Perspectives on the Evolving Treatment of EGFR-mutated Advanced and Metastatic NSCLC

Gain in-depth knowledge on the latest data and guideline recommendations to optimize treatment with targeted therapies for patients with EGFR-mutated advanced or metastatic NSCLC in the first-line setting and beyond, through an on-demand webcast with accompanying slides and an expert-authored ClinicalThought commentary.

Share

Program Content

Activities

EGFR-Mutant NSCLC
Expert Perspectives on the Evolving Treatment of EGFR-Mutated Advanced and Metastatic NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 29, 2024

Expires: May 28, 2025

Activities

ASCO 2024 EGFR Mutated NSCLC
Expert Perspectives on the Evolving Treatment of EGFR-Mutated Advanced and Metastatic NSCLC
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2024

Expires: June 11, 2025

Activities

FAQs: EGFRmut NSCLC
Evolving Treatment Landscape of EGFR-Mutated Advanced and Metastatic NSCLC: Answers to Frequently Asked Questions
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 28, 2024

Expires: June 27, 2025

Faculty

cover img faculity

Nicolas Girard, MD, PhD

Professor
Chair of Medical Oncology
Head of the Thorax Institute Curie-Montsouris
Institut Curie
Universite Paris-Saclay
Paris, France

cover img faculity

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

cover img faculity

Karen Reckamp, MD, MS

Director, Division of Medical Oncology
Associate Director, Clinical Research
Clinical Professor, Department of Medicine
Cedars-Sinai
Los Angeles, California

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Boehringer Ingelheim Pharmaceuticals, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC